论文部分内容阅读
曾有人报道,钙离子通道阻滞剂能降低食管下端括约肌(LES)的压力,改善食管失弛缓症的症状。本文报道了采用安慰剂对照、双盲交叉研究来评估口服硝苯啶、异搏定对LES压力、食管收缩幅度和临床症状的作用。 8例有吞咽困难病史平均2年(2月～7年),并经内镜、X线吞钡、食管测压证实的食管失弛缓症患者中男7例、女1例,平均年龄45岁(20～60岁)。患者随机先服用10mg硝苯啶、80mg异搏定或安慰剂,每日三次,于餐前1小时服用,共两周。然后剂量加倍继续服两周。每服两周药物进行临床评价,每服一种药物结束时(四周)进行食管测压、药物血浓度测定并记录临床表现。各例患者然后转为服第二种药物,4周后再转为服第三种药。试验结束时有1例患者未服完异搏定,2例未服完安慰剂。用配对资料t检验比较用药前
It has been reported that calcium channel blockers can reduce the pressure of the lower esophageal sphincter (LES), to improve the symptoms of esophageal achalasia. We report the use of placebo-controlled, double-blind crossover studies to evaluate the effects of oral nifedipine and verapamil on LES stress, esophageal contractility, and clinical symptoms. 8 patients with history of dysphagia average 2 years (February to 7 years), and endoscopic, X-ray barium swallow, esophageal acupuncture confirmed esophageal achalasia patients, 7 males and 1 females, mean age 45 years (20 to 60 years old). Patients were randomized to take 10 mg of nifedipine, 80 mg of verapamil or placebo at random three times a day for 1 week before taking a total of two weeks. Then dose doubling continue to serve two weeks. The clinical evaluation of each drug for two weeks per serving, at the end of each drug (four weeks) for esophageal manometry, drug blood concentration determination and record the clinical manifestations. Each patient was then converted to the second drug and then to the third drug 4 weeks later. One patient did not receive verapamil at the end of the trial, and two did not receive placebo. Paired data t test before comparison